Battling Ploidy and Purity: Molecular Characterization of Malignant Mesothelioma
Dr. Adrian Dubuc
Wednesday, August 3, 2016
Tweet
Transcript
Embed
Email
Bookmark
<<
<
>
>>
Tweet
Facebook
Email
Chapters
Introduction
Disclosures
Overview
Malignant Mesothelioma (MM)
Treating Mesothelioma
Malignant Mesothelioma (MM) at BWH
Role & Challenges of Pathology
Role & Challenges of Pathology: Inter-institutional histological discordance can be as high as 25%
A Cytogenetic Approach
MM at Brigham and Women’s
Genomics Characterization of M
Genomics Characterization of MM: Mesothelioma is (largely) driven by copy number aberrations
Choosing the most appropriate array
Rapid, Reliable and Reproducible
Mesothelioma Genes of Interest (GOI)
Tumor-Specific Reporting Practices
Tumor-Specific Reporting Practices: CNS Tumors
Tumor-Specific Reporting Practices: Mesothelioma
Array-based analysis of Mesothelioma
Bioinformatic prediction of ploidy
Bioinformatic prediction of ploidy: Chart
Summary & Future Directions
No transcript for this webinar
More Information
Request info
The views and opinions expressed by the guest speakers are solely their own and do not necessarily represent the views or opinions of Affymetrix, Inc.
Any Affymetrix product(s) referenced in this presentation are
For Research Use Only. Not for use in diagnostic procedures.
Please see
affymetrix.com/trademarks
for a complete list of Affymetrix trademarks. All other trademarks are the property of their respective owners.